Impact Therapeutics, a Shanghai, China-based biopharmaceutical company, raised an undisclosed amount in Series D1 funding.
The round was led by Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management with participation from LAV, China Summit, and Yuexiu.
The company intends to use the funds to accelerate the development of its synthetic lethality programs.
Led by CEO Dr. Jun Bao, Impact Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. The company has assembled one of the most comprehensive DNA damage response (DDR) global pipelines of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China.